(Q38123275)

English

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems

scientific article published on 19 July 2013

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

29 August 2017

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems (English)

1 reference

stated in

Europe PubMed Central

29 August 2017

1 reference

1 reference

1 reference

2

1 reference

stated in

Europe PubMed Central

29 August 2017

3

Marc Flajolet

1 reference

stated in

Europe PubMed Central

29 August 2017

Lars Brichta

1

1 reference

stated in

Europe PubMed Central

29 August 2017

19 July 2013

1 reference

stated in

Europe PubMed Central

29 August 2017

Trends in Neurosciences

1 reference

stated in

Europe PubMed Central

29 August 2017

36

1 reference

stated in

Europe PubMed Central

29 August 2017

9

1 reference

stated in

Europe PubMed Central

29 August 2017

543-554

1 reference

stated in

Europe PubMed Central

29 August 2017

Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Homeostatic changes of the endocannabinoid system in Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Dopamine receptors: from structure to function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Amantadine and other antiglutamate agents: management of Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Non-motor symptoms of Parkinson's disease: diagnosis and management

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Development of dyskinesias in a 5-year trial of ropinirole andL-dopa

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Quantitative light microscopic autoradiographic localization of alpha 2-adrenoceptors in the human brain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Distribution of beta‐adrenergic receptor subtypes in human post‐mortem brain: Alterations in limbic regions of schizophrenics

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A controlled trial of antidepressants in patients with Parkinson disease and depression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Presynaptic control of serotonin on striatal dopamine function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Metabotropic glutamate receptors: physiology, pharmacology, and disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Spared caudal brainstem SERT binding in early Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Serotonin 2A receptors and visual hallucinations in Parkinson disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The M5 (m5) receptor subtype: fact or fiction?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

What contributes to quality of life in patients with Parkinson's disease?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Neuronal nicotinic receptors in the human brain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Muscarinic modulation of striatal function and circuitry.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

alpha 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The physiology, signaling, and pharmacology of dopamine receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Rivastigmine for dementia associated with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Brain serotonin transporter binding in non-depressed patients with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A review of central 5-HT receptors and their function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The neurobiology of slow synaptic transmission

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Depression in Parkinson disease--epidemiology, mechanisms and management.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The serotonergic system in Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

The Parkinson's complex: parkinsonism is just the tip of the iceberg

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Modulation of striatal projection systems by dopamine

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Heterologous expression of human {alpha}6{beta}4{beta}3{alpha}5 nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the {alpha}5 subunit

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Unilateral pedunculopontine stimulation improves falls in Parkinson's disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TINS.2013.06.003

Identifiers

DOI

10.1016/J.TINS.2013.06.003

1 reference

stated in

Europe PubMed Central

29 August 2017

1 reference

Europe PubMed Central

PubMed ID

23876424

retrieved

29 August 2017

(Q38123275)

Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)